OnKure Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
OnKure Therapeutics Stock-Based Compensation Growth & History (OKUR)
OnKure Therapeutics's stock-based compensation was $11.6M for fiscal 2025.
View full OnKure Therapeutics company overviewOnKure Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $11.6M | $7.1M | +156.80% |
| 2024 | 2024-12-31 | $4.5M | $4.3M | +2176.38% |
| 2023 | 2023-12-31 | $199,000 | −$4.1M | −95.39% |
| 2022 | 2022-12-31 | $4.3M | $429,000 | +11.03% |
| 2021 | 2021-12-31 | $3.9M | $3.5M | +890.08% |
| 2020 | 2020-12-31 | $393,000 | — | — |
OnKure Therapeutics quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.0M | $141,000 | +4.85% |
| Q1 2026 | 2026-03-31 | $2.8M | $35,000 | +1.28% |
| Q4 2025 | 2025-12-31 | $3.0M | $486,000 | +19.19% |
| Q3 2025 | 2025-09-30 | $3.0M | $2.9M | +3745.45% |
| Q2 2025 | 2025-06-30 | $2.9M | $1.1M | +60.40% |
| Q1 2025 | 2025-03-31 | $2.7M | $2.6M | +2465.42% |
| Q4 2024 | 2024-12-31 | $2.5M | — | — |
| Q3 2024 | 2024-09-30 | $77,000 | −$1.4M | −94.61% |
| Q2 2024 | 2024-06-30 | $1.8M | $606,000 | +50.21% |
| Q1 2024 | 2024-03-31 | $107,000 | −$1.1M | −90.75% |
| Q3 2023 | 2023-09-30 | $1.4M | $439,000 | +44.34% |
| Q2 2023 | 2023-06-30 | $1.2M | $201,000 | +19.98% |
| Q1 2023 | 2023-03-31 | $1.2M | $50,000 | +4.52% |
| Q4 2022 | 2022-12-31 | $1.2M | −$204,000 | −14.36% |
| Q3 2022 | 2022-09-30 | $990,000 | −$155,000 | −13.54% |
| Q2 2022 | 2022-06-30 | $1.0M | $152,000 | +17.80% |
| Q1 2022 | 2022-03-31 | $1.1M | $636,000 | +135.03% |
| Q4 2021 | 2021-12-31 | $1.4M | $1.3M | +1001.55% |
| Q3 2021 | 2021-09-30 | $1.1M | $1.1M | +1263.10% |
| Q2 2021 | 2021-06-30 | $854,000 | $766,000 | +870.45% |
| Q1 2021 | 2021-03-31 | $471,000 | $379,000 | +411.96% |
| Q4 2020 | 2020-12-31 | $129,000 | — | — |
| Q3 2020 | 2020-09-30 | $84,000 | — | — |
| Q2 2020 | 2020-06-30 | $88,000 | — | — |
| Q1 2020 | 2020-03-31 | $92,000 | — | — |
OnKure Therapeutics stock-based compensation trends
Over the last five fiscal years, OnKure Therapeutics's stock-based compensation increased from $393,000 to $11.6M, a change of $11.2M. The latest reported quarter, Q2 2026, shows $3.0M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review OnKure Therapeutics source filings ↗